About
A Paradigm Shift in The Treatment of Demoralization, Anxiety and Depression in Life-Threatening Cancer
We Are Driven to Improve Quality of Life
Psychological and existential distress is common in cancer patients and is associated with poor psychiatric and medical outcomes. More than three million cancer patients in the U.S. experience clinically relevant demoralization, including feelings of anxiety, hopelessness, poor quality of life, and are at higher risk of suicide. They urgently need support and new, effective medicines, as current treatments for these cancer patients are only poorly effective.
Reset Pharma is developing novel, innovative treatments to restore the quality of life to patients with life-threatening cancer experiencing clinically relevant demoralization, anxiety and depression. Our lead program uses psilocybin, a promising novel treatment, to provide both rapid, and long-lasting relief in these patients. To accelerate our lead program, Reset Pharma has acquired an exclusive worldwide license from NYU Langone Health for intellectual property (IP) associated with the use of psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases, including cancer.
Collaboration with Leading Research Institutions to Advance Science and Development
New York University
Reset Pharma has acquired an exclusive worldwide license from NYU Langone Health for intellectual property (IP) associated with the use of psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases, including cancer. This agreement is based on the seminal work of Stephen Ross, M.D., a world leader in advancing research on psychedelic medicine and a prominent addiction psychiatrist. Dr. Ross’ research principally focuses on the use of psilocybin and related psychedelics for the treatment of mood disorders in patients with life-threatening cancer.
Supported by Leading Investors
Palo Santo
Palo Santo is a psychedelic therapeutics investment fund dedicated to increasing the global supply of clinically effective and accessible healthcare solutions. In additional to capital, Palo Santo brings an interdisciplinary team of investment professionals, scientists, researchers, and mental health advocates focused on advancing innovative solutions for CNS disorders. Palo Santo targets high growth opportunities within biotech & drug development, health care services, and digital health solutions led by passionate, experienced, and ethical management teams.